Andrea H. Ramirez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea H. Ramirez has a total of 424 co-authors. Here are the top co-authors by number of shared publications:
- Joshua C. Denny
National Institutes of Health
5 shared publications - Cheryl Renee Clark
Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States
3 shared publications - Dan M. Roden
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
3 shared publications Elizabeth Cohn
3 shared publicationsEric Boerwinkle
3 shared publicationsLucila Ohno-Machado
3 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18  (875)
Frequency of pharmacogenomic variation and medication exposures among participants in the All of Us Research Program
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in pharmacogenomics studies impedes clinical translation and the application of precision medicine across populations. We evaluated the frequencies of variants in 16 pharmacogenes ( ABCG2 , CACNA1S , CYP2D6 , CYP2C Cluster , CYP2C19 , CYP2C9 , CYP3A5 , CYP4F2 , DPYD , G6PD , NUDT15 , RYR1 , SLCO1B1 , TPMT , UGT1A1 , and VKORC1 ) and predicted phenotypes and medication exposures using whole-genome sequencing and electronic health record data from nearly 100,000 All of Us Research Program participants. We report that 100% of participants carried at least one pharmacogenomic variant and nearly all (99.5%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with 24.4% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18  (875)
Frequency of pharmacogenomic variation and medication exposures among participants in the All of Us Research Program
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in pharmacogenomics studies impedes clinical translation and the application of precision medicine across populations. We evaluated the frequencies of variants in 16 pharmacogenes ( ABCG2 , CACNA1S , CYP2D6 , CYP2C Cluster , CYP2C19 , CYP2C9 , CYP3A5 , CYP4F2 , DPYD , G6PD , NUDT15 , RYR1 , SLCO1B1 , TPMT , UGT1A1 , and VKORC1 ) and predicted phenotypes and medication exposures using whole-genome sequencing and electronic health record data from nearly 100,000 All of Us Research Program participants. We report that 100% of participants carried at least one pharmacogenomic variant and nearly all (99.5%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with 24.4% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.
- Top Cited PapersOpen Access
- 27 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32  (6) , 2302-2310
The All of Us Research Program’s wearables dataset
Digital health technologies (DHTs) are revolutionizing medical research, offering unprecedented insights into health monitoring and disease detection through continuous, real-world data collection. Here we characterize the data in one of the largest and most demographically rich DHT datasets as part of the All of Us Research Program. Through a historic device distribution effort, the program reached a broad range of participants nationwide, yielding a DHT dataset with an expanded a large demographic scope. This dataset contains Fitbit data from more than 59,000 participants spanning 14 years with more than 39 million step observations and 31 million sleep observations. Nearly half (46%) of participants with Fitbit data also contributed electronic health records, physical measurements, genomics and survey data. This resource enables researchers to study relationships between digital health metrics and clinical outcomes, advancing DHT methodologies through its large size, broad representation and multi-modal data linkage.
- 27 April 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32  (6) , 2302-2310
Top Cited PapersOpen AccessThe All of Us Research Program’s wearables dataset
Digital health technologies (DHTs) are revolutionizing medical research, offering unprecedented insights into health monitoring and disease detection through continuous, real-world data collection. Here we characterize the data in one of the largest and most demographically rich DHT datasets as part of the All of Us Research Program. Through a historic device distribution effort, the program reached a broad range of participants nationwide, yielding a DHT dataset with an expanded a large demographic scope. This dataset contains Fitbit data from more than 59,000 participants spanning 14 years with more than 39 million step observations and 31 million sleep observations. Nearly half (46%) of participants with Fitbit data also contributed electronic health records, physical measurements, genomics and survey data. This resource enables researchers to study relationships between digital health metrics and clinical outcomes, advancing DHT methodologies through its large size, broad representation and multi-modal data linkage.
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8  (8) , e2400052
Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the All of Us Research Program
PURPOSE: The specific aims of this paper are to (1) develop and operationalize an electronic health record (EHR) data quality framework, (2) apply the dimensions of the framework to the phenotype and treatment pathways of ductal carcinoma in situ (DCIS) using All of Us Research Program data, and (3) propose and apply a checklist to evaluate the application of the framework. METHODS: We developed a framework of five data quality dimensions (DQD; completeness, concordance, conformance, plausibility, and temporality). Participants signed a consent and Health Insurance Portability and Accountability Act authorization to share EHR data and responded to demographic questions in the Basics questionnaire. We evaluated the internal characteristics of the data and compared data with external benchmarks with descriptive and inferential statistics. We developed a DQD checklist to evaluate concept selection, internal verification, and external validity for each DQD. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) concept ID codes for DCIS were used to select a cohort of 2,209 females 18 years and older. RESULTS: Using the proposed DQD checklist criteria, (1) concepts were selected and internally verified for conformance; (2) concepts were selected and internally verified for completeness; (3) concepts were selected, internally verified, and externally validated for concordance; (4) concepts were selected, internally verified, and externally validated for plausibility; and (5) concepts were selected, internally verified, and externally validated for temporality. CONCLUSION: This assessment and evaluation provided insights into data quality for the DCIS phenotype using EHR data from the All of Us Research Program. The review demonstrates that salient clinical measures can be selected, applied, and operationalized within a conceptual framework and evaluated for fitness for use by applying a proposed checklist.
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8  (8) , e2400052
Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the All of Us Research Program
PURPOSE: The specific aims of this paper are to (1) develop and operationalize an electronic health record (EHR) data quality framework, (2) apply the dimensions of the framework to the phenotype and treatment pathways of ductal carcinoma in situ (DCIS) using All of Us Research Program data, and (3) propose and apply a checklist to evaluate the application of the framework. METHODS: We developed a framework of five data quality dimensions (DQD; completeness, concordance, conformance, plausibility, and temporality). Participants signed a consent and Health Insurance Portability and Accountability Act authorization to share EHR data and responded to demographic questions in the Basics questionnaire. We evaluated the internal characteristics of the data and compared data with external benchmarks with descriptive and inferential statistics. We developed a DQD checklist to evaluate concept selection, internal verification, and external validity for each DQD. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) concept ID codes for DCIS were used to select a cohort of 2,209 females 18 years and older. RESULTS: Using the proposed DQD checklist criteria, (1) concepts were selected and internally verified for conformance; (2) concepts were selected and internally verified for completeness; (3) concepts were selected, internally verified, and externally validated for concordance; (4) concepts were selected, internally verified, and externally validated for plausibility; and (5) concepts were selected, internally verified, and externally validated for temporality. CONCLUSION: This assessment and evaluation provided insights into data quality for the DCIS phenotype using EHR data from the All of Us Research Program. The review demonstrates that salient clinical measures can be selected, applied, and operationalized within a conceptual framework and evaluated for fitness for use by applying a proposed checklist.
- Open Access
Frequency of pharmacogenomic variation and medication exposures among All of Us Participants
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine. We evaluated the frequencies of PGx variants, predicted phenotypes, and medication exposures using whole genome sequencing and EHR data from nearly 100k diverse All of Us Research Program participants. We report 100% of participants carried at least one pharmacogenomics variant and nearly all (99.13%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with over 20% having both an actionable phenotype and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we also report hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, including within admixed American and African ancestry groups.
Open AccessFrequency of pharmacogenomic variation and medication exposures among All of Us Participants
Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in studies impedes clinical translation and equitable application of precision medicine. We evaluated the frequencies of PGx variants, predicted phenotypes, and medication exposures using whole genome sequencing and EHR data from nearly 100k diverse All of Us Research Program participants. We report 100% of participants carried at least one pharmacogenomics variant and nearly all (99.13%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with over 20% having both an actionable phenotype and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we also report hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, including within admixed American and African ancestry groups.
- 18 November 2022
- Published by SAGE Publications in Journal of Transcultural Nursing
- Vol. 34  (1) , 59-67
Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey
Background: Underrepresented persons are often not included in biomedical research. It is unknown if the general Asian American population is being represented in All of Us . The purpose of this study was to compare the Asian demographic data in the All of Us cohort with the Asian nationally representative data from the American Community Survey. Method: Demographic characteristics and health literacy of Asians in All of Us were examined. Findings were qualitatively compared with the Asian data in the 2019 American Community Survey 1-year estimate. Results: Compared with the national composition of Asians, less All of Us participants were born outside the United States (64% vs 79%), were younger, and had higher levels of education (76% vs 52%). Over 60% of All of Us participants reported high levels of health literacy. Conclusion: This study had implications for the development of strategies that ensure diverse populations are represented in biomedical research.
- 18 November 2022
- Published by SAGE Publications in Journal of Transcultural Nursing
- Vol. 34  (1) , 59-67
Achieving a Representative Sample of Asian Americans in Biomedical Research Through Community-Based Approaches: Comparing Demographic Data in the All of Us Research Program With the American Community Survey
Background: Underrepresented persons are often not included in biomedical research. It is unknown if the general Asian American population is being represented in All of Us . The purpose of this study was to compare the Asian demographic data in the All of Us cohort with the Asian nationally representative data from the American Community Survey. Method: Demographic characteristics and health literacy of Asians in All of Us were examined. Findings were qualitatively compared with the Asian data in the 2019 American Community Survey 1-year estimate. Results: Compared with the national composition of Asians, less All of Us participants were born outside the United States (64% vs 79%), were younger, and had higher levels of education (76% vs 52%). Over 60% of All of Us participants reported high levels of health literacy. Conclusion: This study had implications for the development of strategies that ensure diverse populations are represented in biomedical research.
- Top Cited PapersOpen Access
The All of Us Research Program: Data quality, utility, and diversity
- Open Access
- 9 April 2022
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 29  (7) , 1131-1141
Comparing medical history data derived from electronic health records and survey answers in the All of Us Research Program
A participant’s medical history is important in clinical research and can be captured from electronic health records (EHRs) and self-reported surveys. Both can be incomplete, EHR due to documentation gaps or lack of interoperability and surveys due to recall bias or limited health literacy. This analysis compares medical history collected in the All of Us Research Program through both surveys and EHRs. The All of Us medical history survey includes self-report questionnaire that asks about diagnoses to over 150 medical conditions organized into 12 disease categories. In each category, we identified the 3 most and least frequent self-reported diagnoses and retrieved their analogues from EHRs. We calculated agreement scores and extracted participant demographic characteristics for each comparison set. The 4th All of Us dataset release includes data from 314 994 participants; 28.3% of whom completed medical history surveys, and 65.5% of whom had EHR data. Hearing and vision category within the survey had the highest number of responses, but the second lowest positive agreement with the EHR (0.21). The Infectious disease category had the lowest positive agreement (0.12). Cancer conditions had the highest positive agreement (0.45) between the 2 data sources. Our study quantified the agreement of medical history between 2 sources—EHRs and self-reported surveys. Conditions that are usually undocumented in EHRs had low agreement scores, demonstrating that survey data can supplement EHR data. Disagreement between EHR and survey can help identify possible missing records and guide researchers to adjust for biases.
- 9 April 2022
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 29  (7) , 1131-1141
Open AccessComparing medical history data derived from electronic health records and survey answers in the All of Us Research Program
A participant’s medical history is important in clinical research and can be captured from electronic health records (EHRs) and self-reported surveys. Both can be incomplete, EHR due to documentation gaps or lack of interoperability and surveys due to recall bias or limited health literacy. This analysis compares medical history collected in the All of Us Research Program through both surveys and EHRs. The All of Us medical history survey includes self-report questionnaire that asks about diagnoses to over 150 medical conditions organized into 12 disease categories. In each category, we identified the 3 most and least frequent self-reported diagnoses and retrieved their analogues from EHRs. We calculated agreement scores and extracted participant demographic characteristics for each comparison set. The 4th All of Us dataset release includes data from 314 994 participants; 28.3% of whom completed medical history surveys, and 65.5% of whom had EHR data. Hearing and vision category within the survey had the highest number of responses, but the second lowest positive agreement with the EHR (0.21). The Infectious disease category had the lowest positive agreement (0.12). Cancer conditions had the highest positive agreement (0.45) between the 2 data sources. Our study quantified the agreement of medical history between 2 sources—EHRs and self-reported surveys. Conditions that are usually undocumented in EHRs had low agreement scores, demonstrating that survey data can supplement EHR data. Disagreement between EHR and survey can help identify possible missing records and guide researchers to adjust for biases.
- Open Access
- 28 December 2021
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 4  (4) , ooab112
Pediatric data from the All of Us research program: demonstration of pediatric obesity over time
The All of Us Research Program is collecting the most diverse and large collection of health data in the United States for research use. The availability and potential of personal health and electronic health record data from participants during childhood has not yet been explored. This article highlights pediatric data available in All of Us and demonstrates its research use by analyzing trends in pediatric obesity over time. We replicated the increase, over 3 decades, in obesity diagnosis for participants during childhood that coincided with increased body mass index measurements which more likely continued as participants became adults. This work demonstrates the utility of large and diverse population health data to accelerate pediatric research by highlighting diagnosis and measurement of pediatric obesity over time.
- 28 December 2021
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 4  (4) , ooab112
Open AccessPediatric data from the All of Us research program: demonstration of pediatric obesity over time
The All of Us Research Program is collecting the most diverse and large collection of health data in the United States for research use. The availability and potential of personal health and electronic health record data from participants during childhood has not yet been explored. This article highlights pediatric data available in All of Us and demonstrates its research use by analyzing trends in pediatric obesity over time. We replicated the increase, over 3 decades, in obesity diagnosis for participants during childhood that coincided with increased body mass index measurements which more likely continued as participants became adults. This work demonstrates the utility of large and diverse population health data to accelerate pediatric research by highlighting diagnosis and measurement of pediatric obesity over time.
- Open Access
- 29 October 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5  (12) , bvab162
Integrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes
Clinical and pathologic heterogeneity in type 1 diabetes is increasingly being recognized. Findings in the islets and pancreas of a 22-year-old male with 8 years of type 1 diabetes were discordant with expected results and clinical history (islet autoantibodies negative, hemoglobin A1c 11.9%) and led to comprehensive investigation to define the functional, molecular, genetic, and architectural features of the islets and pancreas to understand the cause of the donor’s diabetes. Examination of the donor’s pancreatic tissue found substantial but reduced β-cell mass with some islets devoid of β cells (29.3% of 311 islets) while other islets had many β cells. Surprisingly, isolated islets from the donor pancreas had substantial insulin secretion, which is uncommon for type 1 diabetes of this duration. Targeted and whole-genome sequencing and analysis did not uncover monogenic causes of diabetes but did identify high-risk human leukocyte antigen haplotypes and a genetic risk score suggestive of type 1 diabetes. Further review of pancreatic tissue found islet inflammation and some previously described α-cell molecular features seen in type 1 diabetes. By integrating analysis of isolated islets, histological evaluation of the pancreas, and genetic information, we concluded that the donor’s clinical insulin deficiency was most likely the result autoimmune-mediated β-cell loss but that the constellation of findings was not typical for type 1 diabetes. This report highlights the pathologic and functional heterogeneity that can be present in type 1 diabetes.
- 29 October 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5  (12) , bvab162
Open AccessIntegrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes
Clinical and pathologic heterogeneity in type 1 diabetes is increasingly being recognized. Findings in the islets and pancreas of a 22-year-old male with 8 years of type 1 diabetes were discordant with expected results and clinical history (islet autoantibodies negative, hemoglobin A1c 11.9%) and led to comprehensive investigation to define the functional, molecular, genetic, and architectural features of the islets and pancreas to understand the cause of the donor’s diabetes. Examination of the donor’s pancreatic tissue found substantial but reduced β-cell mass with some islets devoid of β cells (29.3% of 311 islets) while other islets had many β cells. Surprisingly, isolated islets from the donor pancreas had substantial insulin secretion, which is uncommon for type 1 diabetes of this duration. Targeted and whole-genome sequencing and analysis did not uncover monogenic causes of diabetes but did identify high-risk human leukocyte antigen haplotypes and a genetic risk score suggestive of type 1 diabetes. Further review of pancreatic tissue found islet inflammation and some previously described α-cell molecular features seen in type 1 diabetes. By integrating analysis of isolated islets, histological evaluation of the pancreas, and genetic information, we concluded that the donor’s clinical insulin deficiency was most likely the result autoimmune-mediated β-cell loss but that the constellation of findings was not typical for type 1 diabetes. This report highlights the pathologic and functional heterogeneity that can be present in type 1 diabetes.
- Open Access
- 24 July 2018
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 8  (3) , 24
Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey
Genetic medicine is one of the key components of personalized medicine, but adoption in clinical practice is still limited. To understand potential barriers and provider attitudes, we surveyed 285 physicians from five Implementing GeNomics In pracTicE (IGNITE) sites about their perceptions as to the clinical utility of genetic data as well as their preparedness to integrate it into practice. These responses were also analyzed in comparison to the type of study occurring at the physicians’ institution (pharmacogenetics versus disease genetics). The majority believed that genetic testing is clinically useful; however, only a third believed that they had obtained adequate training to care for genetically “high-risk” patients. Physicians involved in pharmacogenetics initiatives were more favorable towards genetic testing applications; they found it to be clinically useful and felt more prepared and confident in their abilities to adopt it into their practice in comparison to those participating in disease genetics initiatives. These results suggest that investigators should explore which attributes of clinical pharmacogenetics (such as the use of simplified genetics-guided recommendations) can be implemented to improve attitudes and preparedness to implement disease genetics in care. Most physicians felt unprepared to use genetic information in their practice; accordingly, major steps should be taken to develop effective clinical tools and training strategies for physicians.
- 24 July 2018
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 8  (3) , 24
Open AccessPhysician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey
Genetic medicine is one of the key components of personalized medicine, but adoption in clinical practice is still limited. To understand potential barriers and provider attitudes, we surveyed 285 physicians from five Implementing GeNomics In pracTicE (IGNITE) sites about their perceptions as to the clinical utility of genetic data as well as their preparedness to integrate it into practice. These responses were also analyzed in comparison to the type of study occurring at the physicians’ institution (pharmacogenetics versus disease genetics). The majority believed that genetic testing is clinically useful; however, only a third believed that they had obtained adequate training to care for genetically “high-risk” patients. Physicians involved in pharmacogenetics initiatives were more favorable towards genetic testing applications; they found it to be clinically useful and felt more prepared and confident in their abilities to adopt it into their practice in comparison to those participating in disease genetics initiatives. These results suggest that investigators should explore which attributes of clinical pharmacogenetics (such as the use of simplified genetics-guided recommendations) can be implemented to improve attitudes and preparedness to implement disease genetics in care. Most physicians felt unprepared to use genetic information in their practice; accordingly, major steps should be taken to develop effective clinical tools and training strategies for physicians.